Pharma Tech
| 2023年 平成35年 |
- | Why increased communication are a necessity for good relationships between Contract pharma(2023年)Evolving approaches in project managementDCAT Value Chain Insights also wanted to gain a perspectiv… Reposted from WuXi STA(2023年)WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing ca… Reposted from WuXi STA(2023年)More information on Custom peptide synthesisJoin WuXi STA at IOPC 2022 in Milan, Italy to learn how… New peptide manufacturing method could produce cheaper medicines(2023年)New peptide manufacturing method could produce cheaper medicinesScientists have developed a new met… New Peptide synthesis manufacturing method could produce cheaper medicines(2023年)In collaboration with Eli Lilly and the University of KwaZulu-Natal, a team in the Department of C… WuXi TIDES Adds New Peptide Manufacturing Capacity and Large-Scale Continuous Purification System(2023年)Expansion Enhances WuXi TIDES CRDMO Platform Capability and Capacity for Global Partners April 5, 2… New technology offers fast Peptide synthesis(2023年)Automated manufacturing could make it easier to develop and test new Peptide synthesis drugs.Manufa… WuXi STA Starts Construction of New Site in Taixing China(2023年)On April 28, 2021, STA Pharmaceutical, a WuXi AppTec company, announced the construction of its Tai… WuXi STA Opens New Drug Product Facility in Wuxi City Site(2023年)Wuxi city, China, May 20, 2021- STA Pharmaceutical, a WuXi AppTec company, today announces the open… WuXi TIDES Adds New Peptide Manufacturing Capacity and Large-Scale Continuous Purification System(2023年)Expansion Enhances WuXi TIDES CRDMO Platform Capability and Capacity for Global Partners April 5, 2… WuXi STA Forms Strategic Partnership with Coherent Biopharma(2023年)SHANGHAI, CHINA，WuXi STA – a subsidiary of WuXi AppTec– and Coherent Biopharma, announced the sign… WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation(2023年)SINGAPORE, July 19, 2022 – WuXi AppTec, a leading global provider of R&D and manufacturing serv… WuXi STA Launches its First Parenteral Formulation Manufacturing Line(2023年)Shanghai, China, January 21, 2022 - WuXi STA, a subsidiary of WuXi AppTec, today announced its firs… Reposted from WuXi STA(2023年)Facility Spotlight: Recently, we opened another large-scale API plant with 277 m3 total reactor vol… Reposted from WuXi STA(2023年)What are the most significant issues shaping the pharma customer-supplier relationship in 2022? Dr.… Reposted from WuXi STA(2023年)Recently we completed the expansion of the enzyme fermentation plant as part of our biocatalysis pl… Reposted from WuXi STA(2023年)WuXi STA today announced its first parenteral formulation manufacturing line at the Wuxi city site … Reposted from WuXi STA(2023年)Our Shanghai Waigqaoqiao site successfully passed its first drug product pre-approval inspection (P… Reposted from WuXi STA(2023年)WuXi STA became the preferred partner of Coherent Biopharma to accelerate their diverse pipeline of… Reposted from WuXi STA(2023年)Visit our new website ( to learn how our end-to-end discovery to commercial peptide CRDMO platform … New technology offers fast Peptide synthesis(2023年)New technology offers fast Peptide synthesisAutomated manufacturing could make it easier to develop… Reposted from WuXi STA(2023年)We appreciate the “Platinum Service Awards” from Teon Therapeutics to recognize WuXi STA’s outstand… Reposted from WuXi STA(2023年)Technology spotlight: WuXi STA’s flow chemistry platform continually expands. We recently launched … Reposted from WuXi STA(2023年)Do you have an oligonucleotide, peptide, or related conjugate in your pipeline? WuXi STA has built … Peptide synthesis factory powered by artificial intelligence(2023年)IIT-Madras uses machine learning to help create newer, useful Peptide synthesisBY M RAMESHResearche… Another major challenge for the market peptide synthesis(2023年)Restraints:The high cost associated with peptide synthesis is a major restraint for the market. The… Key Trends in the Peptide Synthesis Market(2023年)Current Trends and Innovations:One of the key trends in the peptide synthesis market is the develop… Global Peptide Synthesis Market Segmentation(2023年)Emergen Research has segmented the global peptide synthesis market on the basis of product type, te… Tthe leading companies in the Global Global Peptide Therapeutics market(2023年)The following are the leading companies in the Global Global Peptide Therapeutics market:Pfizer Inc… WuXi STA Forms Strategic Partnership with Ark Biopharmaceutical for the Commercial Supply of Ziresovir(2023年)SHANGHAI, CHINA, May 23, 2023 - WuXi STA, a subsidiary of WuXi AppTec, and Shanghai Ark Biopharmace… WuXi TIDES Adds New Peptide Manufacturing Capacity and Large-Scale Continuous Purification System(2023年)Expansion Enhances WuXi TIDES CRDMO Platform Capability and Capacity for Global Partners April 5, 2… WuXi STA Launches First Continuous Manufacturing Line for Oral Solids(2023年)SHANGHAI, CHINA, January 3, 2023 – WuXi STA, a subsidiary of WuXi AppTec, today announced that its … Three Sites from WuXi STA Receive Top EcoVadis Scores for Business Sustainability Rating(2023年)WuXi STA, a subsidiary of WuXi AppTec, received the latest scores from EcoVadis rating, a trusted p… WuXi STA and Multiply Labs announce partnership and successfully deploy robotic manufacturing system for personalized drugs(2023年)Personalized doses now can be filled into single - or multi - compartment capsules for GMP manufact… WuXi STA Forms Strategic Partnership with Insilico Medicine(2023年)SHANGHAI, CHINA, September 1, 2022 – WuXi STA, a subsidiary of WuXi AppTec, and Insilico Medicine, … WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers(2023年)Shanghai, China, September 9, 2022 – WuXi STA, a subsidiary of WuXi AppTec, today announced the ope… WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility(2023年)New facility expands integrated drug product R&D and manufacturing services to global customers… WuXi STA Successfully Passes Four Pre-Approval Inspections by South Korea's Ministry of Food and Drug Safety at Three Manufacturing Sites in China(2023年)SHANGHAI, CHINA, October 12, 2022 – WuXi STA, a leading global Contract Research, Development, and … WuXi STA Opens a New Clinical Supply Service Facility at Shanghai Waigaoqiao Site(2023年)New service further accelerates drug candidates to clinical trials through CRDMO platform Shanghai,… WuXi STA Launches Another Parenteral Formulation Manufacturing Line at Wuxi City Site(2023年)Shanghai, China, November 30, 2022 – WuXi STA, a subsidiary of WuXi AppTec, today announced a new p… WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware(2023年)MIDDLETOWN, Delaware, August 16, 2022 – WuXi STA, a leading Contract Research, Development, and Man… WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation(2023年)SINGAPORE, July 19, 2022 – WuXi AppTec, a leading global provider of R&D and manufacturing serv… WuXi STA Opens a New Large Scale Continuous Manufacturing Plant at Changzhou Site(2023年)Company continues to enhance the flow chemistry platform for more sustainable productionShanghai, C… WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility(2023年)Site Enhances New Modality CRDMO Platform Capacity for CustomersShanghai, China, July 7, 2022 - WuX… WuXi STA Opens Another High-Potency API Plant in Changzhou, China(2023年)Shanghai, China – June 24, 2022 – WuXi STA, a WuXi AppTec company, has opened another high-potency … WuXi STA Passes the First EMA Drug Product Pre-Approval Inspection at its Wuxi City Site(2023年)SHANGHAI, CHINA, March, 3, 2022 –WuXi STA – a subsidiary of WuXi AppTec – today announced that its … WuXi STA Forms Strategic Partnership with Xynomic Pharma(2023年)SHANGHAI, CHINA, WuXi STA – a subsidiary of WuXi AppTec– and Xynomic Pharmaceuticals (Nanjing) Co.,… WuXi STA and Hua Medicine Sign Supply Agreement for Dorzagliatin(2023年)SHANGHAI, CHINA, WuXi STA – a subsidiary of WuXi AppTec– and Hua Medicine (SEHK stock code: 2552.HK… WuXi STA Launches its First Parenteral Formulation Manufacturing Line(2023年)Shanghai, China, January 21, 2022 - WuXi STA, a subsidiary of WuXi AppTec, today announced its firs… WuXi STA Passes the First U.S. FDA Drug Product Pre-Approval Inspection at its Shanghai Waigaoqiao Site(2023年)SHANGHAI, CHINA, January 4, 2022 – WuXi STA – a subsidiary of WuXi AppTec, announced that its Waiga… WuXi STA Chooses Middletown Delaware for New Pharmaceutical Manufacturing Campus(2023年)WuXi STA bringing about 500 jobs to MiddletownWILMINGTON, Del. (June 28, 2021) — WuXi STA and Delaw… WuXi STA Forms Strategic Partnership with InnoCare(2023年)SHANGHAI, CHINA, July, 16, 2021 –STA Pharmaceutical Co., Ltd., a WuXi AppTec Company (WuXi STA)–and… WuXi STA Forms Strategic Partnership with BioNova(2023年)STA Pharmaceutical Co., Ltd., a WuXi AppTec Company (WuXi STA)–and BioNova Pharmaceuticals (Shangha… WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland(2023年)State-of-the-art facility significantly enhances WuXi STA's drug product capacity in Europe wh… Hoth Therapeutics Sign API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT(2023年)WuXi STA is a leading manufacturer of GMP morpholino oligonucleotides (PMOs)NEW YORK, November 8, 2… WuXi STA Forms Strategic Partnership with Coherent Biopharma(2023年)SHANGHAI, CHINA，WuXi STA – a subsidiary of WuXi AppTec– and Coherent Biopharma, announced the sign… WuXi STA Forms Strategic Partnership with Ascentage Pharma(2023年)SHANGHAI, CHINA, June, 3, 2021 –STA Pharmaceutical Co., Ltd., (“WuXi STA”), a leading Contract Deve… WuXi STA Opens New Drug Product Facility in Wuxi City Site(2023年)Wuxi city, China, May 20, 2021- STA Pharmaceutical, a WuXi AppTec company, today announces the open… WuXi STA and WuXi Biologics Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services(2023年)Shanghai, CHINA, May 14, 2021 –WuXi STA, a subsidiary of WuXi AppTec and WuXi Biologics (“WuXi Bio”… WuXi STA Starts Construction of New Site in Taixing China(2023年)On April 28, 2021, STA Pharmaceutical, a WuXi AppTec company, announced the construction of its Tai… Three WuXi STA Facilities Pass Pre-Approval Inspection From NMPA(2023年)SHANGHAI, CHINA, April, 12, 2021 – STA Pharmaceutical, a WuXi AppTec company (WuXi STA), a leading … WuXi STA Forms Strategic Partnership with AnHeart to Accelerate the Development of Novel Oncology Therapies(2023年)SHANGHAI, CHINA, March, 15, 2021 –STA Pharmaceutical Co., Ltd., (“WuXi STA”), a leading Contract De… WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland(2023年)NEW YORK & SHANGHAI -- Bristol Myers Squibb (NYSE: BMY) and WuXi STA – a subsidiary of WuXi App… WuXi STA, WuXi Biologics and Antengene Announce Collaboration to Advance Antibody-Drug Conjugate Candidate into Clinical Stage(2023年)Shanghai China, February 1, 2021— STA Pharmaceutical Co., Ltd., (“WuXi STA”) , a leading Contract D… WuXi STA's Integrated CMC Platform Supports InnoCare's Orelabrutinib Approved by NMPA(2023年)SHANGHAI, December 25, 2020: The National Medical Products Administration of China (NMPA) announced… Tubulis Forms Strategic Partnership with WuXi STA and WuXi Biologics to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation(2023年)WuXi STA and WuXi Biologics to become Contract Development and Manufacturing Organization (CDMO) pa… WuXi STA Forms Strategic Partnership with BeiGene(2023年)Today, STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and BeiGene, Ltd. (… WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility(2023年)Shanghai, January 3, 2020: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec –… WuXi STA Forms Strategic Partnership with Impact Therapeutics(2023年)STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Impact Therapeutics, a… WuXi STA's Jinshan Facility Passes EMA Inspection(2023年)SHANGHAI, October 28, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec … WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections(2023年)SHANGHAI, 23 July, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – a… WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement(2023年)STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, … WuXi STA's New Drug Product Manufacturing Facility Passes First European MPA GMP Inspection(2023年)SHANGHAI, March 27, 2019 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., (WuXi STA) - a subsidiary of… WuXi STA Forms Strategic Partnership with Beta Pharma(2023年)STA will Accelerate Process R&D and Manufacturing of Late Phase and Commercial Targets STA Phar… WuXi STA Forms Strategic Partnership with Beta Pharma(2023年)STA will Accelerate Process R&D and Manufacturing of Late Phase and Commercial Targets STA Phar… WuXi STA and Ark Biosciences Sign CMC Development and Manufacturing Agreement(2023年)STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Ark Biosciences, a glo… WuXi STA and BioLingus sign exclusive technology and marketing collaboration for sublingual delivery(2023年)SHANGHAI and SAN DIEGO, Feb. 18, 2019 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., (WuXi STA), a s… Peptide synthesis factory powered by artificial intelligence (Part 2)(2023年)Peptide synthesis factory powered by artificial intelligence (Part 2)The AI would come up with a pe… BIS Issues Proposed Rule for Section 1758 Technology Export Controls on Instruments for the Automated Chemical Synthesis of Peptide synthesis(2023年)BIS Issues Proposed Rule for Section 1758 Technology Export Controls on Instruments for the Automat… WuXi STA Receives 2023 CDMO Leadership Award in Recognition of Capabilities and Reliabilities(2023年)WuXi STA, a global leading Contract Research, Development, and Manufacturing Organization (CRDMO), … WuXi STA Wins 2022 CMO Leadership Awards in All Six Core Categories(2023年)Shanghai, China, February 8, 2022 - WuXi STA, a subsidiary of WuXi AppTec, today announced that it … WuXi STA Received 2020 CDMO Award from Roche(2023年)WuXi STA was announced as the winner of Roche's "2020 CDMO Award" for the best proje… 2021, WuXi STA Again Wins CMO Leadership Awards in All Six Core Categories(2023年)STA Pharmaceutical Co., Ltd., (“WuXi STA”) , a leading Contract Development and Manufacturing Organ… Dr. Ge Li Awarded “CEO of the Year” at CPhI Worldwide 2019(2023年)November 11, 2019: WuXi AppTec, a leading global provider of R&D and manufacturing services ena… Dr. Ge Li Awarded “CEO of the Year” at CPhI Worldwide 2019(2023年)November 11, 2019: WuXi AppTec, a leading global provider of R&D and manufacturing services ena… |
| 12月 | Peptide Synthesis Market Size Worth USD 954.3 Million in 2030 | Emergen Research(2023年12月)VANCOUVER, BC, Feb. 27, 2023 /PRNewswire/ -- The Peptide Synthesis Market size was valued at USD 50… Global peptide synthesis Therapeutics Market to hit new heights worth US$ 70.14 Billion by 2030: Growth Plus Reports(2023年12月14日)Newark, New Castle, USA Growth Plus Reports most recent study examines the Global Global peptide s… |
- この年表のURL:
